Acticor Biotech (Biopharma, Biotechnology) — Funding, Investors & Signals 2026

Acticor Biotech

To treat the acute phase of ischemic stroke !

Founded 2013 France

France 18 employees Post Ipo Equity Total: $49.30M Biopharma, Biotechnology +2

Acticor Biotech, a spin-off from Inserm (French National Institute of Health and Medical Research), is focused on developing an innovative therapeutic strategy for the acute phase of ischemic strokes, which constitute 80% of all strokes. The company's project addresses the pressing need for new therapeutic options to manage stroke, considering that 15 million people worldwide suffer from stroke each year, resulting in 5 million deaths and 5 million permanent disabilities. Stroke ranks as the third leading cause of death globally and the primary cause among women, while 75% of survivors sustain neurological damage leading to acquired disabilities. Currently, only one treatment is recommended by health authorities, reaching merely 15% of ischemic stroke patients with less than 40% efficacy. This underscores a substantial need for a new and more effective treatment. Acticor Biotech's project relies on the academic research from its founders, Dr. M. Jandrot-Perrus and Prof. P. Billiald, and has garnered support from prestigious institutions such as the ANR (The French National Research Agency) and the Fondation de France. The project has also been recognized with the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly OSEO). Founded in 2013 and headquartered in France, Acticor Biotech recently secured an €8.00M Post-IPO Equity investment on 15 March 2024, with investment from UI Investissement, Mediolanum Farmaceutici S.p.A., Gilles Avenard, and Alain Munoz. The company operates in the Biopharma, Biotechnology, Health and Wellness, and Pharmaceutical industries, positioning itself at the forefront of innovative medical advancements to address critical unmet healthcare needs related to ischemic stroke.

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Equity	••••••	4	•••• ••••	15 Mar 2024
Post-IPO Equity	••••••	1	•••• ••••	09 Mar 2023
Series B	••••••	7	•••• ••••	06 Nov 2019
Series B	••••••	4	•••• ••••	17 Oct 2018
Series A	••••••	3		04 Jan 2018

Funding Stage

Amount

Investors

Lead Investors

Date

Post-IPO Equity

••••••

•••• ••••

15 Mar 2024

Post-IPO Equity

••••••

•••• ••••

09 Mar 2023

Series B

••••••

•••• ••••

06 Nov 2019

Series B

••••••

•••• ••••

17 Oct 2018

Series A

••••••

04 Jan 2018

FAQ About Acticor Biotech

To treat the acute phase of ischemic stroke !

Acticor Biotech was founded in 2013.

Acticor Biotech is headquartered in France.

Acticor Biotech operates in the following industries: Biopharma, Biotechnology, Health and Wellness, Pharmaceutical.

Acticor Biotech has approximately 18 employees.

Acticor Biotech has completed 9 funding rounds, raising a total of $49.30M. The latest funding stage is Post Ipo Equity.

Acticor Biotech offers: Drug development for thrombotic diseases.

Top alternatives and competitors to Acticor Biotech include Time is Brain, advanceCor GmbH, Genethon, Soligenix, Inc., Emmes' Rare Disease and Pediatric Center. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Acticor Biotech and Time is Brain are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Acticor Biotech

General Information

Track Acticor Biotech

Discover More

About Acticor Biotech

Services & Products

Target Customers

Funding Rounds & Investors (9)

Acticor Biotech Alternatives & Competitors

FAQ About Acticor Biotech

Don't just browse. Track.